Current AD research focuses on understanding pathology by targeting several mechanisms, such as abnormal tau protein metabolism, -amyloid, inflammatory response, and cholinergic and free radical damage, aiming to develop successful treatments that are capable of stopping or modifying the course of AD (Tamagno et al., 2021)
Khoo, J., Hsiang, J., Taneja, R., Law, N.-M
Many patients experience an average weight loss of 10% to 18% of their starting body weight, and some lose 15% to 21% of their body weight over 68 weeks, depending in part on starting weight
Wakabayashi A, Tojo Y, Baron-Cohen S, Wheelwright S
A peptide half-life chart lists the time required for the plasma concentration of each peptide to decrease by 50% after administration